Regeneron Sinks As Sales Of Key Eye Medication Tumble -- Market Talk

Dow Jones

昨天

1404 ET - Regeneron missed analysts' 1Q sales and earnings targets, driven by a 26% decline in sales of Eylea, the company's blockbuster vision-loss drug. Doctors are opting for lower-cost alternatives, in part because of problems Medicare patients are having getting copay assistance from nonprofit foundations funded by the pharmaceutical industry. Regeneron is trying to get other drugmakers to match its donations to the foundations so their programs are better funded, CEO Leonard Schleifer tells analysts. Regeneron sinks 7%; the stock has fallen 36% over the past 12 months as the company adjusts to generic competition for Eylea. (joseph.walker@wsj.com)

(END) Dow Jones Newswires

April 29, 2025 14:04 ET (18:04 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2531767519"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531767519\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2531767519?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-30 02:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531767519","market":"us","top_or_hot":-1,"title":"Regeneron Sinks As Sales Of Key Eye Medication Tumble -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1404 ET - Regeneron missed analysts' 1Q sales and earnings targets, driven by a 26% decline in sales of Eylea, the company's blockbuster vision-loss drug. Doctors are opting for lower-cost alternatives, in part because of problems Medicare patients are having getting copay assistance from nonprofit foundations funded by the pharmaceutical industry. Regeneron is trying to get other drugmakers to match its donations to the foundations so their programs are better funded, CEO Leonard Schleifer tells analysts. Regeneron sinks 7%; the stock has fallen 36% over the past 12 months as the company adjusts to generic competition for Eylea. (joseph.walker@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2025 14:04 ET (18:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron Sinks As Sales Of Key Eye Medication Tumble -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron Sinks As Sales Of Key Eye Medication Tumble -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-04-30 02:04</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1404 ET - Regeneron missed analysts' 1Q sales and earnings targets, driven by a 26% decline in sales of Eylea, the company's blockbuster vision-loss drug. Doctors are opting for lower-cost alternatives, in part because of problems Medicare patients are having getting copay assistance from nonprofit foundations funded by the pharmaceutical industry. Regeneron is trying to get other drugmakers to match its donations to the foundations so their programs are better funded, CEO Leonard Schleifer tells analysts. Regeneron sinks 7%; the stock has fallen 36% over the past 12 months as the company adjusts to generic competition for Eylea. (joseph.walker@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2025 14:04 ET (18:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REGN","symbol_name":"再生元製藥公司","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2531767519","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531767519","pubTimestamp":1745949840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1404 ET - Regeneron missed analysts' 1Q sales and earnings targets, driven by a 26% decline in sales of Eylea, the company's blockbuster vision-loss drug. Doctors are opting for lower-cost alternatives, in part because of problems Medicare patients are having getting copay assistance from nonprofit foundations funded by the pharmaceutical industry. Regeneron is trying to get other drugmakers to match its donations to the foundations so their programs are better funded, CEO Leonard Schleifer tells analysts. Regeneron sinks 7%; the stock has fallen 36% over the past 12 months as the company adjusts to generic competition for Eylea. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"REGN":"再生元制药公司"},"translate_title":"再生元(Regeneron)因主要眼科药物销量下滑而下滑——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":0.9},"content_text":"1404 ET - Regeneron missed analysts' 1Q sales and earnings targets, driven by a 26% decline in sales of Eylea, the company's blockbuster vision-loss drug. Doctors are opting for lower-cost alternatives, in part because of problems Medicare patients are having getting copay assistance from nonprofit foundations funded by the pharmaceutical industry. Regeneron is trying to get other drugmakers to match its donations to the foundations so their programs are better funded, CEO Leonard Schleifer tells analysts. Regeneron sinks 7%; the stock has fallen 36% over the past 12 months as the company adjusts to generic competition for Eylea. (joseph.walker@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  April 29, 2025 14:04 ET (18:04 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}